You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
1. For symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion: Duodenal ulcer; Gastric ulcer; Gastro-oesophageal reflux disease (GORD) i. Symptomatic GORD. The treatment of heartburn and other symptoms associated with GORD ii. Reflux oesophagitis; Gastrointestinal lesions refractory to H2 blockers ; Zollinger-Ellison Syndrome. Patients whose gastric or duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (NSAIDs) require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. 2. Maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. 3. For eradication of Helicobacter pylori, treatment with pantoprazole and one of the following combinations of antibiotics: Clarithromycin and amoxicillin or; Clarithromycin and metronidazole or; Amoxicillin and metronidazole - is recommended in cases of duodenal ulcer and gastric ulcer with the objective of reducing the recurrence of duodenal and gastric ulcers caused by this micro-organism. 4. Pantoprazole in combination with bismuth, metronidazole and tetracycline is indicated for the eradication of Helicobacter pylori associated with peptic ulcer disease with the objective of reducing the recurrence of peptic ulcers caused by this organism. 5. Prevention of gastroduodenal lesions and dyspeptic symptoms associated with non-selective non-steroidal anti-inflammatory drugs (NSAIDs) in increased risk patients with a need for continuous non-selective NSAID treatment.
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
1. For symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion: Duodenal ulcer; Gastric ulcer; Gastro-oesophageal reflux disease (GORD) i. Symptomatic GORD. The treatment of heartburn and other symptoms associated with GORD ii. Reflux oesophagitis; Gastrointestinal lesions refractory to H2 blockers ; Zollinger-Ellison Syndrome. Patients whose gastric or duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (NSAIDs) require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. 2. Maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. 3. For eradication of Helicobacter pylori, treatment with pantoprazole and one of the following combinations of antibiotics: Clarithromycin and amoxicillin or; Clarithromycin and metronidazole or; Amoxicillin and metronidazole - is recommended in cases of duodenal ulcer and gastric ulcer with the objective of reducing the recurrence of duodenal and gastric ulcers caused by this micro-organism. 4. Pantoprazole in combination with bismuth, metronidazole and tetracycline is indicated for the eradication of Helicobacter pylori associated with peptic ulcer disease with the objective of reducing the recurrence of peptic ulcers caused by this organism. 5. Prevention of gastroduodenal lesions and dyspeptic symptoms associated with non-selective non-steroidal anti-inflammatory drugs (NSAIDs) in increased risk patients with a need for continuous non-selective NSAID treatment.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on November, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
1. For symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion: Duodenal ulcer; Gastric ulcer; Gastro-oesophageal reflux disease (GORD) i. Symptomatic GORD. The treatment of heartburn and other symptoms associated with GORD ii. Reflux oesophagitis; Gastrointestinal lesions refractory to H2 blockers ; Zollinger-Ellison Syndrome. Patients whose gastric or duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (NSAIDs) require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. 2. Maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. 3. For eradication of Helicobacter pylori, treatment with pantoprazole and one of the following combinations of antibiotics: Clarithromycin and amoxicillin or; Clarithromycin and metronidazole or; Amoxicillin and metronidazole - is recommended in cases of duodenal ulcer and gastric ulcer with the objective of reducing the recurrence of duodenal and gastric ulcers caused by this micro-organism. 4. Pantoprazole in combination with bismuth, metronidazole and tetracycline is indicated for the eradication of Helicobacter pylori associated with peptic ulcer disease with the objective of reducing the recurrence of peptic ulcers caused by this organism. 5. Prevention of gastroduodenal lesions and dyspeptic symptoms associated with non-selective non-steroidal anti-inflammatory drugs (NSAIDs) in increased risk patients with a need for continuous non-selective NSAID treatment.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on November, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
